Skip to main content
Feedback
Home

Professional Education / Transfusion

Learn.Share.Advance

Secondary Menu

  • Overview
  • Contact
  • Blog
  • EN
  • FR
  • EN
  • FR

Main menu

  • Transfusion
  • Organs and Tissues

Secondary Menu Mobile

  • Overview
  • Contact
  • Blog

Main navigation

  • Virtual tour
  • Events
      • Past events
  • Courses
      • LearnTransfusion series
      • AFC-diploma program in transfusion medicine
      • Genomics Transfusion Rounds
      • Sickle cell disease education program for health-care professionals
      • BloodTechNet educational resources
      • KnowledgeInfusion
      • Transfusion Camp
        • Medical Residents Transfusion Camp 2024-2025
        • Pediatric Transfusion Camp 2024-2025
        • Nurse Practitioners Transfusion Camp 2024 - 2025
        • Rwanda Transfusion Camp 2024 Staff
        • Rwanda Transfusion Camp 2024 trainees
        • United Kingdom Transfusion Camp 2024-2025
      • Other courses and learning resources
  • Clinical guide
      • Chapter 1 - Vein to vein: A summary of the blood system in Canada
      • Chapter 2 - Blood components
      • Chapter 3 - Albumin
      • Chapter 4 - Immunoglobulin products
      • Chapter 5 - Concentrates for hemostatic disorders and hereditary angioedema
      • Chapter 6 - Donor selection, donor testing and pathogen reduction
      • Chapter 7 - Fractionated blood products and associated pathogen safety
      • Chapter 8 - Pre-transfusion testing
      • Chapter 9 - Blood administration
      • Chapter 10 - Transfusion reactions
      • Chapter 11 - Massive hemorrhage and emergency transfusion
      • Chapter 12 - Hemolytic disease of the fetus and newborn and perinatal immune thrombocytopenia
      • Chapter 13 - Neonatal and pediatric transfusion
      • Chapter 14 - Therapeutic apheresis
      • Chapter 15 - Irradiated, washed and CMV seronegative blood components
      • Chapter 16 - Preoperative autologous donation
      • Chapter 17 - Hemostatic disorders and hereditary angioedema
      • Chapter 18 - Platelet transfusion, alloimmunization and management of platelet refractoriness
      • Chapter 19 - Pathogen-reduced platelets
      • Chapter 20 - Granulocyte transfusion therapy
  • Best practices
      • Breakthroughs in blood: Advancing practice through research
      • Blood utilization best practices
        • Blood System Inventory Management Best Practices Guide
        • Platelet clinical best practices
      • Uniform labelling
      • International Collaboration for Transfusion Medicine Guidelines (ICTMG)
      • Risk-based decision-making framework
      • Informed consent for blood transfusion
      • Red cell antigen genotyping reports
        • Red cell antigen genotyping report: A quick glance
        • Interpreting the red cell antigen genotyping report
      • Serological best practices
        • ABO subgroups
        • Diego system: anti-Dia
        • Diego system: anti-Wra
        • Kell System: Anti-Kpa
        • Kell system: anti-Jsa
        • Lewis system: anti-Lewis
        • Lutheran system: anti-Lua
        • MNS system: anti-M
        • Rh System: Anti-V
        • Rh system: anti-Cw
        • Whole blood donors with antibodies
      • Testing and management of fetal and neonatal alloimmune thrombocytopenia
      • Visual Inspection Tool
        • Red blood cells
          • Red blood cells: Bacterial contamination
          • Red blood cells: Hemolysis
          • Red blood cells: Lipemia
          • Red blood cells: Particulate matter
        • Platelets
          • Platelets: Bacterial contamination
          • Platelets: Bubbles
          • Platelets: Icterus
          • Platelets: Lipemia
          • Platelets: Other causes of discolouration
          • Platelets: Particulate matter
          • Platelets: Red blood cell contamination
        • Plasma
          • Plasma: Bacterial contamination
          • Plasma: Icterus
          • Plasma: Lipemia
          • Plasma: Other causes of discolouration
          • Plasma: Particulate matter
          • Plasma: Red blood cell contamination
        • Cryoprecipitate
          • Cryoprecipitate: Bacterial contamination
          • Cryoprecipitate: Icterus
          • Cryoprecipitate: Other causes of discolouration
          • Cryoprecipitate: Particulate matter
  • Publications
      • Paying it forward: Why we need YOU to give blood
      • National plan for the management of shortages of labile blood components
      • Phenotype matching and storage age of blood for sickle cell patients: A review and recommendations for transfusion practice
      • Anaphylactic transfusion reactions and IgA deficiency
      • Transfusion-related acute lung injury (TRALI)
      • Emergency framework for rationing of blood for massively bleeding patients during a red phase blood shortage
      • Blood bag spiking procedure
      • Platelet product quality remains high after seven days of storage
      • A survey of Canadian MLTs’ views on continuing education in transfusion science
      • A Guide to Reporting Adverse Transfusion Reactions
      • Alternative methods of blood donor skin disinfection
      • Blood: the basics
      • COVID-19
        • COVID-19 FAQ: Information for health professionals on safety of transfused blood collected from COVID-19-vaccinated donors
        • COVID-19: FAQ for health professionals working with blood products
        • FAQ: SARS-CoV-2 antibodies in immunoglobulin products
      • Exploring the frontiers of IVIG-associated hemolysis
      • FAQ: Canadian Blood Services platelet bacterial screening
      • FAQ: Delisting of directed donations at Canadian Blood Services
      • FAQ: Donor high titre isohemagglutinin (anti-A/anti-B) testing at Canadian Blood Services
      • FAQ: Information for health professionals on apheresis platelet psoralen-treated (APPT) and untreated apheresis platelet in PAS-E
      • FAQ: Information for health professionals on pathogen-reduced platelets
      • FAQ: Information for health professionals ordering granulocyte concentrates
      • FAQ: Solvent detergent (S/D) treated plasma (Octaplasma)
        • Octaplasma: One-page clinical summary
      • FAQ: Whole blood, leukocytes reduced, at Canadian Blood Services
      • Impact of COVID-19 on blood donation in Canada
      • Solvent detergent (S/D) treated plasma (Octaplasma)
      • Striking the balance: protecting data privacy in research
      • Summary of adverse transfusion reactions 2019-2024
      • Surveillance report
      • The importance of iron for whole blood donors: a Canadian perspective
  • Links
      • Canadian Society for Transfusion Medicine (CSTM)
      • National Advisory Committee on Blood and Blood Products
      • Provincial blood coordinating offices
      • Reference standards
      • Textbooks
      • Transfusionnews.com
      • Other links
  1. Transfusion
  2. Links

Provincial blood coordinating offices

Alberta Blood Coordinating Program

B.C. Provincial Blood Coordinating Office (PBCO)

Manitoba, Best Blood

Nova Scotia Provincial Blood Coordinating Program

Newfoundland and Labrador Provincial Blood Coordinating Program

Ontario Regional Blood Coordinating Network (ORBCoN)

Saskatchewan Provincial Blood Office

 

 

© 2025 Canadian Blood Services. All rights reserved.

  • blood.ca
  • Contact us
  • Privacy policy
  • Legal